Patient Care

Advances in Targeted Therapy for Breast Cancer

Author and Disclosure Information

 

References

Disclaimer
The opinions expressed herein are those of the authors and do not necessarily reflect those of Federal Practitioner, Frontline Medical Communications Inc., the U.S. Government, or any of its agencies. This article may discuss unlabeled or investigational use of certain drugs. Please review complete prescribing information for specific drugs or drug combinations—including indications, contraindications, warnings, and adverse effects—before administering pharmacologic therapy to patients.

Click here to read the digital edition.

Pages

Recommended Reading

VIDEO: Multiple PARP inhibitors show promise in breast cancer treatment
Breast Cancer ICYMI
VIDEO: It’s too early to give up on immunotherapy for breast cancer
Breast Cancer ICYMI
VIDEO: Genomics, other advances further highlight how breast cancer differs in men
Breast Cancer ICYMI
VIDEO: Residual cancer burden may be better outcome measure than pCR
Breast Cancer ICYMI
VIDEO: Sexuality, fertility are focus of cancer education website
Breast Cancer ICYMI
FDA approves ribociclib for HR+, HER2– advanced breast cancer
Breast Cancer ICYMI
Breast cancer info on centers’ sites leaves room for improvement
Breast Cancer ICYMI
Unavoidable, random DNA replication errors are the most common cancer drivers
Breast Cancer ICYMI
Survivorship care models work, some better than others
Breast Cancer ICYMI
Safe to avoid sentinel node biopsy in some breast cancer patients
Breast Cancer ICYMI